LIVE
SGMO
Sangamo Therapeutics, Inc. · Healthcare
$0.07
N/A this month
VERSUS
⟷
COMPARE
CRSP
CRISPR Therapeutics AG · Healthcare
$50.81
+2.03% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
SGMO
2
CRSP
1
Comparison scoreboard
SGMO LEADS 2/5AI Score
SGMO 34.1
CRSP ✓38.3
1Y Return
SGMO N/A
CRSP -9.94%
Fwd P/E
SGMO ✓-0.74
CRSP -13.13
Target Up.
SGMO ✓+1927.03%
CRSP +66.70%
Op. Margin
SGMO N/A
CRSP N/A
Metrics last refreshed: 7/14/2026
Quick take
SGMO vs CRSP: Sangamo vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
Sangamo is a gene editing pioneer using zinc finger nuclease technology with pharma partnerships, while CRISPR Therapeutics has achieved the world's first CRISPR therapy approval and has a more advanced clinical pipeline. CRISPR Therapeutics is the more advanced gene editing company; Sangamo's ZFN technology is older and faces competitive challenges from CRISPR-based approaches.
SGMO vs CRSP is a legacy zinc finger gene editing platform with pharma partnerships versus the CRISPR gene editing leader with an approved therapy — CRISPR Therapeutics has validated its platform with regulatory approval; Sangamo depends on clinical execution in a more competitive landscape.
Live analysis · updated 7/14/2026
SGMO holds the edge across 2 of 5 key metrics in this comparison. Analyst consensus implies meaningfully more upside for SGMO (+1927.03%) than for CRSP (+66.70%).
Normalized 1Y performance
SGMO
CRSP
Not enough data to chart yet.
Recent returns
SGMO
CRSP
Analyst price targets & sentiment
SGMO · 2 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$1.00
analyst high$2.00
analyst mean$1.50
current price$0.07
+1927.0% upside to analyst mean
CRSP · 20 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$44.00
analyst high$291.00
analyst mean$84.70
current price$50.81
+66.7% upside to analyst mean
Who should consider this stock?
SGMO may suit investors who:
- →want exposure to zinc finger nuclease gene editing at a lower valuation than CRISPR companies
- →believe Sangamo's pharma partnerships provide milestone income that de-risks cash burn
- →are comfortable with higher clinical execution risk and a more competitive technology position
- →prefer a diversified pipeline spanning hemophilia, neurology, and cell therapy at low absolute price
CRSP may suit investors who:
- →want the gene editing company with the first approved CRISPR therapy validating the platform
- →value Vertex partnership as commercial infrastructure that reduces CRSP's revenue uncertainty
- →prefer a more advanced gene editing company with both approved products and a diversified pipeline
- →are comfortable with Casgevy market adoption uncertainty in exchange for platform validation
Performance & AI score
| Metric | SGMO | CRSP |
|---|---|---|
| AI score | 34.1 | 38.3 |
| AI rank | #1846 | #1357 |
| Latest close | $0.07 | $50.81 |
| 1M return | N/A | +2.03% |
| 6M return | N/A | -8.12% |
| 1Y return | N/A | -9.94% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | SGMO | CRSP |
|---|---|---|
| 1Y ago | N/A | $9.01K (-9.9%) started 2025-07-14 |
| 5Y ago | N/A | $3.9K (-61.0%) started 2021-07-14 |
| 10Y ago | N/A | $36.06K (+260.6%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | SGMO | CRSP |
|---|---|---|
| Market cap | $30.66M | $5B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -0.74 | -13.13 |
| Price/Sales | 0.89 | 1219.59 |
| EV/Revenue | 0.30 | 787.00 |
| Analyst target | $1.50 | $84.70 |
| Target upside | +1927.03% | +66.70% |
Growth, profitability & risk
| Metric | SGMO | CRSP |
|---|---|---|
| Revenue growth | -77.60% | 68.60% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -140.57% | -6358.66% |
| Operating margin | N/A | N/A |
| Profit margin | 0.00% | 0.00% |
| ROIC proxy | N/A | -31.21% |
| Return on equity | N/A | -31.21% |
| Dividend yield | N/A | 0.00% |
| Beta | 1.29 | 1.70 |
| Debt/equity | N/A | 43.41 |
| Current ratio | 0.70 | 17.96 |
| Quick ratio | 0.64 | 17.92 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
SGMO max drawdownN/A
CRSP max drawdown42.25%
SGMO max wkly dropN/A
CRSP max wkly drop18.19%
5Y risk snapshot
SGMO max drawdownN/A
CRSP max drawdown77.31%
SGMO max wkly dropN/A
CRSP max wkly drop21.49%
10Y risk snapshot
SGMO max drawdownN/A
CRSP max drawdown85.11%
SGMO max wkly dropN/A
CRSP max wkly drop30.47%
Performance metrics by period
| Period | Metric | SGMO | CRSP |
|---|---|---|---|
| 1Y | Growth | N/A | -9.94% |
| CAGR | N/A | -9.95% | |
| Sharpe ratio | N/A | 0.07 | |
| Max drawdown | N/A | 42.25% | |
| Max daily drop | N/A | 11.59% | |
| Max wkly drop | N/A | 18.19% | |
| 5Y | Growth | N/A | -61.01% |
| CAGR | N/A | -17.17% | |
| Sharpe ratio | N/A | -0.09 | |
| Max drawdown | N/A | 77.31% | |
| Max daily drop | N/A | 13.32% | |
| Max wkly drop | N/A | 21.49% | |
| 10Y | Growth | N/A | +260.61% |
| CAGR | N/A | +14.09% | |
| Sharpe ratio | N/A | 0.45 | |
| Max drawdown | N/A | 85.11% | |
| Max daily drop | N/A | 17.10% | |
| Max wkly drop | N/A | 30.47% |
Business comparison
| Category | SGMO | CRSP |
|---|---|---|
| Company | Sangamo Therapeutics, Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Pioneer in zinc finger nuclease (ZFN) gene editing with a diversified pipeline in hemophilia, neurological diseases, and cell therapy. Sangamo has technology licensing partnerships with major pharma (Pfizer, Biogen, Novartis). | Gene editing company with the world's first approved CRISPR therapy (Casgevy for sickle cell disease) co-developed with Vertex Pharmaceuticals, plus pipeline programs in diabetes, oncology, and in vivo editing. |
| Investor focus | Clinical program success in hemophilia and neurological diseases, partner milestone payments, ZFN vs CRISPR competitive position, and cash runway management. | Casgevy commercial ramp, CTX112 diabetes program, CAR-T oncology pipeline, and next-generation in vivo CRISPR delivery. |
SGMO strengths
- →Sangamo has 25+ years of zinc finger nuclease experience — a deep IP estate in gene editing that predates CRISPR
- →Pharmaceutical partnerships (Pfizer, Biogen) provide non-dilutive funding through milestones and royalties
- →Zinc finger nucleases have achieved proof-of-concept in clinical settings, validating the underlying technology
CRSP strengths
- →Casgevy is the world's first approved CRISPR therapy — a major competitive and scientific milestone
- →Vertex partnership provides commercial capability without full CRSP commercial infrastructure buildout
- →Pipeline diversification into diabetes, oncology, and in vivo delivery provides multiple paths to value
Risks to watch — SGMO
- →ZFN technology is generally considered less efficient and harder to program than CRISPR-Cas9 — competitive disadvantage in newer programs
- →Multiple clinical setbacks have eroded investor confidence in Sangamo's pipeline execution
- →Cash management is critical as Sangamo has faced several restructuring cycles
Risks to watch — CRSP
- →Casgevy's high cost and complex treatment process limit near-term commercial scale
- →Base editing and prime editing competitors (Beam, Prime Medicine) may offer improved precision
- →In vivo delivery for CRISPR remains technically challenging and largely unproven in patients
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →